{"entity":{"id":"gc101-til","kind":"drug","name":"GC101 TIL","aka":[],"tldr":"GC101 TIL is an experimental tumour-infiltrating lymphocyte therapy from Shanghai Juncell Therapeutics in phase 2 trials for melanoma, aimed at PD-1 and BRAF.","summary":"GC101 TIL (GC101) is a tumour-infiltrating lymphocyte therapy developed by Shanghai Juncell Therapeutics. Its targets are PD-1, BRAF and MEK1/2 (the sponsor names melanoma and non-small cell lung cancer (solid tumours)). The sponsor states: An autologous natural TIL cell therapy administered without high-intensity lymphodepleting chemotherapy and without IL-2 administration. ClinicalTrials.gov describes the intervention as: Patients with advanced melanoma (excluding uveal melanoma) who have failed to PD-1 antibodies (if BRAF mutation is present, BRAF and MEK inhibitors have failed; if NRAS mutation is present, tunlametinib have failed) and are ineligible for r. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in melanoma. The largest, NCT06703398, plans to enrol 98 participants with primary completion was scheduled for 2026-05-12 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of GC101 TIL","url":"https://clinicaltrials.gov/search?intr=GC101"},{"label":"Sponsor page","url":"https://www.juncell.com/"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":["pd1","braf","mek"],"drugs":[],"companies":["shanghai-juncell-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06703398","nct07560111"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"GC101","modality":"TIL therapy","mechanism":"An autologous natural TIL cell therapy administered without high-intensity lymphodepleting chemotherapy and without IL-2 administration.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/gc101-til/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"target":[{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/"},{"id":"mek","kind":"target","name":"MEK1/2","route":"/targets/mek/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"company":[{"id":"shanghai-juncell-therapeutics","kind":"company","name":"Shanghai Juncell Therapeutics","route":"/companies/shanghai-juncell-therapeutics/"}],"trial":[{"id":"nct07560111","kind":"trial","name":"A Phase II Study of GC101 in NSCLC","route":"/trials/nct07560111/"},{"id":"nct06703398","kind":"trial","name":"A Study of GC101 TIL in Advanced Melanoma","route":"/trials/nct06703398/"}]}}